Pacific Biosciences Of California (PACB) Asset Writedowns and Impairment (2022 - 2026)

Pacific Biosciences Of California has reported Asset Writedowns and Impairment for 5 years, with the latest figure at $54000.0 in Q1 2026.

• For the quarter ending Q1 2026, Asset Writedowns and Impairment fell 99.64% year-over-year to $54000.0; the trailing twelve-month figure through Mar 2026 stood at $54000.0 (down 99.96% YoY), and the FY2025 full-year result was $15.0 million, down 62.5% from the prior year.
• Asset Writedowns and Impairment for Q1 2026 stood at $54000.0, down from $15.0 million in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $93.2 million in Q2 2024, with the low at -$4.7 million in Q4 2023.
• Average Asset Writedowns and Impairment over 5 years is $11.1 million, with a median of $774000.0 recorded in 2023.
• Year-over-year, Asset Writedowns and Impairment sank 99.91% in 2024 and surged 499900.0% in 2025.
• Tracing PACB's Asset Writedowns and Impairment over 5 years: stood at -$2.7 million in 2022, then plunged by 75.89% to -$4.7 million in 2023, then soared by 873.5% to $36.3 million in 2024, then sank by 58.66% to $15.0 million in 2025, then plunged by 99.64% to $54000.0 in 2026.
• The last three Asset Writedowns and Impairment figures came in at $54000.0 (Q1 2026), $15.0 million (Q1 2025), and $36.3 million (Q4 2024), per Business Quant data.

Peer Comparison